title: Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.
authors.forename: A
authors.initials: A
authors.lastname: Karras
authors.forename: C
authors.initials: C
authors.lastname: Rabian
authors.forename: H
authors.initials: H
authors.lastname: Zylberberg
authors.forename: O
authors.initials: O
authors.lastname: Hermine
authors.forename: V
authors.initials: V
authors.lastname: Duchatelle
authors.forename: F
authors.initials: F
authors.lastname: Durand
authors.forename: D
authors.initials: D
authors.lastname: Valla
authors.forename: J P
authors.initials: JP
authors.lastname: Viard
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015497:HIV-1; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D019469:Indinavir / Q000009:adverse effects* / Q000627:therapeutic use; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009336:Necrosis; D012010:Red-Cell Aplasia, Pure / Q000150:complications*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir